The Gastroparesis Market size is projected to reach US$ 7.39 billion by 2031 from US$ 5.03 billion in 2023. The market is expected to register a CAGR of 4.9% in 2023–2031. Technological advancement and increasing research on gastric electrical stimulation are likely to remain key Gastroparesis Market trends.

Gastroparesis Market Analysis

Gastroparesis is a functional disorder of the stomach affecting nerves and muscles which leads to slower gastric movements. Major factors driving the gastroparesis market growth includes the increasing prevalence of idiopathic gastroparesis followed by the rising prevalence of diabetes mellitus which leads to the gastroparesis. Moreover, the increasing geriatric population contributes to the rising prevalence of gastroparesis owing to inadequate appetite regulation, poor oral medication absorption, and postprandial glycemia. Aging leads to the diminished bodily functions such as physiologic functions and slowing of gastric emptying which influences the motor and sensory functions among the geriatric population.

Gastroparesis Market Overview

The gastroparesis market has seen tremendous growth in last few years owing to the increasing awareness of conditions and improved diagnostic techniques and the development of new options. The market players are actively involved in the research and development of effective treatment options which can help in the effective management of the condition. Moreover, effective technologies such as gastric electrical stimulation are used to improve the gastric mobility among patients with severe gastroparesis. Moreover, increasing research will lead to the development of novel therapies and personalized treatment approaches for the gastroparesis.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Gastroparesis Market: Strategic Insights

Gastroparesis Market

• 
  CAGR (2023 - 2031)

  4.9%
• Market Size 2023
  US$ 5.03 billion
• Market Size 2031
  US$ 7.39 billion

Market Dynamics

GROWTH DRIVERS

• Increasing prevelance of Diabetes Mellitus

FUTURE TRENDS

• Technological Advancements and incresaing research on gastric stimulation

OPPORTUNITIES

• Surging Clinical Trials

Key Players

• EVOKE PHARMA
• Bausch Health Companies Inc.(Salix Pharmaceuticals, Ltd.)
• Johnson And Johnson Services, Inc.
• Allergan Plc
• NEUROGASTRX, INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• Pfizer Inc.
• ANI Pharmaceuticals, Inc.
• Ipca Laboratories Ltd.
• Cinrx Pharma, LLC (Cindome Pharma)

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Idiopathic
• Diabetic
• Post-Surgical
• Others

Drug Class Type

• Prokinetic Agents
• Antiemetic Agents
• Botulinum Toxin Injection

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Gastroparesis Market Drivers and Opportunities

Rising Diabetes Mellitus Prevalence to Favor Market

Diabetes is one of the prominent known causes of gastroparesis. The condition is characterized by damaged nerves, especially involving vagus nerves and stomach wall cells. The damage to vagus nerves affects muscle motility of the stomach and small intestine. According to a study published by Johns Hopkins University, ~30–50% of the diabetic population suffers from delayed gastric emptying. The escalating incidence of diabetes mellitus due to obesity, a sedentary lifestyle, and unhealthy eating habits is propelling the prevalence of gastroparesis.

Increasing Clinical Trials are likely to create Market Opportunities

The increasing prevalence of gastroparesis has created a demand for effective and advanced treatment with better outcomes. This has tremendously increased the number of clinical trials globally which is expected to provide better treatment options to the large patient population by testing the safety and efficacy of the newly developed drugs. Some of the ongoing clinical trails for gastroparesis drugs are mentioned below:

Drug Name	Phase	Status
Relamorelin	3	Recruiting
RM -131	2	Recruiting
Velusetrag	2	Recruiting
Buspirone	2	Completed
Velusetrag	2	Completed
Naronapride	2	Recruiting

Source: Clinicaltrials.gov

Gastroparesis Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Gastroparesis Market analysis are type, drug class, and distribution channel.

• Based on type, the Gastroparesis Market is segmented into idiopathic, diabetic, post-surgical, others. The idiopathic segment held a larger market share in 2023.
• By drug class type, the market is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2023.
• In terms of distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment dominated the market in 2023.

Gastroparesis Market Share Analysis by Geography

The geographic scope of the Gastroparesis Market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the Gastroparesis Market owing to the rising prevalence of gastroparesis. In addition, the aging population and growing prevalence of diabetes are also projected to offer lucrative opportunities for the growth of the North America gastroparesis market during the forecast period. In addition, extensive research in pharmaceutical and biotechnology companies is further expected to stimulate the growth of the gastroparesis market in North America. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Gastroparesis Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Gastroparesis Market News and Recent Developments

The Gastroparesis Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for gastroparesis and strategies:

• The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis. (Source: Vanda Pharmaceuticals, Press Release/Newsletter, 2023)
• The company treated the first participant with its potential best-in-class pan-GI prokinetic, naronapride, in Europe in a Phase IIb trial to treat gastroparesis. (Source: Renexxion Ireland, Press Release/Company Website/Newsletter, 2023)

Gastroparesis Market Report Coverage and Deliverables

The “Gastroparesis Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles